{
    "2021-06-12": [
        [
            {
                "time": "2023-10-18",
                "original_text": "IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leukemia (CLL) Phase 3 GLOW Study",
                "features": {
                    "keywords": [
                        "IMBRUVICA",
                        "ibrutinib",
                        "VENCLEXTA",
                        "VENCLYXTO",
                        "venetoclax",
                        "Superior Progression-Free Survival",
                        "Chlorambucil",
                        "Obinutuzumab",
                        "First-line CLL",
                        "Phase 3 GLOW Study"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}